The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
 
Daneng Li
Consulting or Advisory Role - Adagene; Delcath Systems; Eisai; Exelixis; Genentech; Ipsen; Merck; MINA THERAPEUTICS; QED Therapeutics; Tersera
Speakers' Bureau - Coherus Biosciences; Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Lionel Aurelien Kankeu Fonkoua
No Relationships to Disclose
 
Jean Fan
Employment - TransThera Sciences (Nanjing), Inc.
Leadership - TransThera Sciences (Nanjing), Inc.
Stock and Other Ownership Interests - AstraZeneca
 
Peng Peng
Employment - TransThera Sciences (Nanjing), Inc.
Stock and Other Ownership Interests - TransThera Sciences (Nanjing), Inc.
Patents, Royalties, Other Intellectual Property - PCT/CN2022/091924 (Inst)
 
Hui Wang
No Relationships to Disclose
 
Brenda Ngo
No Relationships to Disclose
 
Caixia Sun
Employment - TransThera Sciences (Nanjing), Inc.
 
Qinhua Cindy Ru
Employment - CRC Oncology; Xing Zhi Wei Therapeutics
Leadership - CRC Oncology; Xing Zhi Wei Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics; CRC Oncology; Long Sky Industries Limited
Consulting or Advisory Role - ABM; Cellular Biomedicine Group; Help Therapeutics
 
Frank Wu
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Stock and Other Ownership Interests - TransThera Biosciences
Patents, Royalties, Other Intellectual Property - PCT/CN2021077394 (Inst)
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; QED Therapeutics; Taiho Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Taiho Pharmaceutical